Cambridge Life Sciences (CLS) launches ELISA tests for ACL:
This article was originally published in Clinica
Executive Summary
Cambridge Life Sciences (UK) has launched Autozyme ACL, a new range of three ELISA tests for the measurement of IgA, IgG and IgM anti-cardiolipin antibodies (ACL). Research indicates that raised levels of ACL IgA, IgG and IgM are associated with venous and arterial thrombosis, thrombocytopaeni, recurrent foetal loss and myocardial infarction, as well as neurological conditions. The Autozyme assays are compatible, and can be run simultaneously.